Drug Trial Radar · NCT03800017
Skeletal Muscle Function in Interstitial Lung Disease
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 7, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- University of British ColumbiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 10, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Dyspnea (i.e. breathlessness) and exercise intolerance are common symptoms for patients with interstitial lung disease (ILD), yet it is not known why. It has been suggested that muscle dysfunction may contribute to dyspnea and exercise intolerance in ILD. Our study aims to: i) examine differences in the structure and function of the leg muscles in ILD patients, ii) determine if leg muscle fatigue contributes to dyspnea and exercise limitation in patients with ILD, and iii) determine the effects of breathing extra oxygen on leg muscle fatigue, as well as ability to exercise in ILD patients.
Conditions
- Interstitial Lung Disease
- Idiopathic Pulmonary Fibrosis
- Hypersensitivity Pneumonitis
- Scleroderma
- Nonspecific Interstitial Pneumonia
Interventions
HyperoxiaBiological
Participants breathe 60% oxygen during exercise
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in standardized dyspnea score during the constant load exercise test (visit 3)Time frame: Dyspnea will be measured once every minute during exercise on visit 3 (up to 7 weeks after baseline) until participants reach volitional exhaustion (assessed for up to 30 minutes)
- Change in standardized dyspnea score during the constant load exercise test (visit 4)Time frame: Dyspnea will be measured once every minute during exercise on visit 4 (up to 8 weeks after baseline) until participants reach volitional exhaustion (assessed for up to 30 minutes)
- Change in leg muscle strength measured following the constant load exercise test (visit 3)Time frame: Leg muscle strength will be measured before and after exercise (assessed for up to 40 minutes) on visit 3 (up to 8 weeks after baseline)
- Change in leg muscle strength measured following the constant load exercise test (visit 4)Time frame: Leg muscle strength will be measured before and after exercise (assessed for up to 40 minutes) on visit 4 (up to 8 weeks after baseline)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. Paul's Hospital
Vancouver, British Columbia, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.